Historical source coverage
71 selected records with a cited source date in 2022. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Tesamorelin
DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 47 for the reviewed Dulaglutide label family with a published date of 2022-12-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · MOTS-c
PubMed lists PMID 26289118 in Aging cell as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-20 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Afamelanotide
PubMed lists PMID 31987791 in Journal of the American Academy of Dermatology as Letter, Randomized Controlled Trial, with publication-date metadata of 2020-01-25 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 30 for the reviewed Linaclotide label family with a published date of 2022-12-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 46 for the reviewed Dulaglutide label family with a published date of 2022-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Cagrilintide
PeptideScanner retained PubMed bibliographic metadata for PMID 36242844 at 2026-07-30T19:34:05.168Z. PubMed recorded a metadata revision date of 2022-11-29 and an Entrez history date of 2022-10-15. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01796301 at 2026-07-30T19:32:59.853Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03479762 at 2026-07-30T19:32:59.846Z. Its registry update date was 2022-11-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT05153590 at 2026-07-30T19:32:59.847Z. Its registry update date was 2022-11-17, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Safety · Octreotide
FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations.
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Leuprolide
DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Ziconotide
DailyMed lists Structured Product Labeling version 3 for the reviewed Ziconotide label family with a published date of 2022-10-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Pramlintide
DailyMed lists Structured Product Labeling version 13 for the reviewed Pramlintide label family with a published date of 2022-10-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · MOTS-c
PubMed lists PMID 36233287 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2022-10-09 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02064036 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Setmelanotide
PubMed lists PMID 35931197 in Life sciences as Journal Article, with publication-date metadata of 2022-08-02 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Vosoritide
The Federal Register published notice 2022-19155, attributed to FDA and its parent HHS department, on 2022-09-06. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Vosoritide.
Source: Federal Register via GovInfo ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT03255629 at 2026-07-30T19:35:26.311Z. Its registry update date was 2022-09-06, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory · Tirzepatide
The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.
Source: Federal Register via GovInfo ↗
Literature metadata · Pramlintide
PubMed lists PMID 29389581 in Journal of food and drug analysis as Journal Article, with publication-date metadata of 2017-08-24 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Setmelanotide
The Federal Register published notice 2022-16502, attributed to FDA and its parent HHS department, on 2022-08-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Literature metadata · Dulaglutide
PubMed lists PMID 34866291 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Setmelanotide
DailyMed lists Structured Product Labeling version 5 for the reviewed Setmelanotide label family with a published date of 2022-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Setmelanotide
The Federal Register published notice 2022-14134, attributed to FDA and its parent HHS department, on 2022-07-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT04007809 at 2026-07-30T19:38:43.098Z. Its registry update date was 2022-06-28, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Literature metadata · Bremelanotide
PubMed lists PMID 33455598 in CNS spectrums as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-01-18 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 45 for the reviewed Dulaglutide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Lixisenatide
DailyMed lists Structured Product Labeling version 17 for the reviewed Lixisenatide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00775684 at 2026-07-30T19:38:43.099Z. Its registry update date was 2022-06-07, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata · Plecanatide
PubMed lists PMID 32275447 in Organic letters as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-04-10 (day precision). PeptideScanner associated the retained record with the identity slug plecanatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Safety · Dulaglutide
FDA's dated enforcement report D-0884-2022 lists Class II and source status Completed for Cardinal Health Inc. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory · Exenatide + 1 more
The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.
Source: Federal Register via GovInfo ↗
Regulatory · Tirzepatide
The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02664441 at 2026-07-30T19:39:59.673Z. Its registry update date was 2022-05-05, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Setmelanotide
DailyMed lists Structured Product Labeling version 4 for the reviewed Setmelanotide label family with a published date of 2022-04-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02268175 at 2026-07-30T19:40:58.917Z. Its registry update date was 2022-04-19, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Setmelanotide
DailyMed lists Structured Product Labeling version 3 for the reviewed Setmelanotide label family with a published date of 2022-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02765399 at 2026-07-30T19:40:58.914Z. Its registry update date was 2022-04-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Plecanatide
PubMed lists PMID 28169285 in The American journal of gastroenterology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2017-02-07 (day precision). PeptideScanner associated the retained record with the identity slug plecanatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Pramlintide
PubMed lists PMID 21564002 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2011-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Pramlintide
PubMed lists PMID 24169554 in Endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-12-20 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Vosoritide
PubMed lists PMID 35180295 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2022-03-07 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Bremelanotide
PubMed lists PMID 35230162 in Journal of women's health (2002) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-25 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Abaloparatide
PubMed lists PMID 25987981 in BoneKEy reports as Journal Article, with publication-date metadata of 2015-04-29 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Leuprolide
The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 42 for the reviewed Dulaglutide label family with a published date of 2022-02-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Vosoritide
PubMed lists PMID 34694597 in Drugs as Journal Article, Review, with publication-date metadata of 2021-11 (month precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Bremelanotide
PubMed lists PMID 35076581 in Neurology international as Journal Article, Review, with publication-date metadata of 2022-01-04 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03085095 at 2026-07-30T19:44:52.972Z. Its registry update date was 2022-01-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02122198 at 2026-07-30T19:44:52.962Z. Its registry update date was 2022-01-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT03262610 at 2026-07-30T19:44:52.963Z. Its registry update date was 2022-01-04, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗